Skip to main content
Top

10-11-2017 | Nephropathy | News

Salt restriction boosts losartan benefits in type 2 diabetes

print
PRINT
insite
SEARCH

medwireNews: Finding from the PROCEED trial show that dietary salt restriction helps to reduce albuminuria in patients with type 2 diabetes taking losartan, the investigators report in The Lancet Diabetes & Endocrinology.

The patients in the study all had macroalbuminuria despite treatment with a renin–angiotensin system inhibitor. All participants switched to losartan 100 mg/day; the 57 who were randomly assigned to a low-sodium diet achieved a median 36.6% reduction in albuminuria between baseline and the end of month 3, with substantial reductions seen from month 1.

Of note, patients in the low-sodium group had been allocated to achieve urine sodium excretion of less than 100 mEq per day (2.4 g of salt per day), but in fact achieved only 170 mEq per day on average, from a baseline of approximately 200 mEq.

“Whether prescription of a very restricted sodium diet is required to achieve moderate sodium restriction, or whether prescription of a moderate sodium restriction might attain the double aim of facilitating compliance and achieving a degree of sodium restriction that has a renoprotective effect, remains unclear,” write Beatriz Fernandez-Fernandez and Alberto Ortiz, both from Universidad Autonoma de Madrid in Spain, in an accompanying commentary.

Patients in the low-salt group were also randomly assigned to take the vitamin D receptor activator paricalcitol 2 µg/day or placebo, but this had no additional effect on albuminuria, report Giuseppe Remuzzi (Istituto di Ricovero e Cura a Carattere Scientifico—Istituto di Ricerche Farmacologiche Mario Negri, Bergamo, Italy) and study co-authors.

However, it was a different story in a further 58 patients who were randomly assigned to a high-salt diet (4.8 g salt/day). Within this group, patients taking placebo had no significant change in albuminuria by the end of month 3, but those taking paricalcitol had a significant 14.7% reduction.

The commentators say that the PROCEED findings “send a clear message in favour of moderate salt restriction for reduction of albuminuria, and a mixed message for paricalcitol treatment.”

Taking the results of the VITAL trial into account, they believe that “any potential renal benefit of paricalcitol is limited to the high dose of 2 μg per day in patients unable or unwilling to decrease salt intake.”

They also raise the issue of safety, with cardiovascular events reported for the 2 µg dose in VITAL, and also in PROCEED (one ischemic heart disease, one stroke), compared with none among patients taking the 1 µg dose (in VITAL) or placebo. And in PROCEED there were also increased rates of hypercalcemia and hyperphosphatemia (5% and 4% vs 0% on placebo) and of hypercalciuria (12% vs 1%).

“This safety signal for paricalcitol is counterintuitive, in view of putative renal and cardiovascular benefits suggested by preclinical data and findings from observational studies,” say Fernandez-Fernandez and Ortiz. “If the association is confirmed, the potential mechanisms remain unclear.”

In the meantime, they say that the 2 µg dose should be used only in a clinical trial setting.

By Eleanor McDermid

medwireNews is an independent medical news service provided by Springer Healthcare. © 2017 Springer Healthcare part of the Springer Nature group

print
PRINT

Be confident that your patient care is up to date

Medicine Matters is being incorporated into Springer Medicine, our new medical education platform. 

Alongside the news coverage and expert commentary you have come to expect from Medicine Matters diabetes, Springer Medicine's complimentary membership also provides access to articles from renowned journals and a broad range of Continuing Medical Education programs. Create your free account »